4D MEDICINE
4D MEDICINE
Total Employee:
11+
Status:
Active
Total Funding:
115 K GBP
Investors List
SFC Capital
SFC Capital investment in Seed Round - 4D Medicine
More informations about "4D Medicine"
4D Medicine | Redefining Excellence in Bioabsorbable Medical โฆ
4D is focused on two critical areas of innovation designed to improve surgical outcomes and enhance patient quality of life worldwide. Biomaterials 4Dโs patented polymer resin platform, 4Degra® , delivers an improved biodegradation profile, enhanced biocompatibility and unique โฆSee details»
Advancing Surgery with Next-Gen Medical Devices
Piers is an experienced finance professional who joined 4D Medicine in 2024. He has more than 20 years Board level experience in drug discovery, clinical development in biotech, covering both small molecules and gene therapies. In โฆSee details»
4DMT Announces RMAT Designation Granted by FDA for 4D-150 โฆ
23 hours ago This designation in DME follows the RMAT designation granted for 4D-150 in wet AMD, and to our knowledge, 4D-150 is the first investigational medicine to be granted the โฆSee details»
4D Medicine | Bioabsorbable Implantable Medical Device Design
4D Medicine collaborates with industry leaders to develop bioabsorbable implantable medical devices using patented 4Degra® polymer. Discover our innovative design and manufacturing โฆSee details»
4D Medicine 2025 Company Profile: Valuation, Funding
4D Medicine General Information Description. Manufacturer of degradable, implantable medical devices made from novel photopolymer materials. The company is taking a range of devices โฆSee details»
4D Medicine: biodegradable and bioabsorbable medical devices
4D Medicine is currently taking its first product, a bioabsorbable interference screw for musculoskeletal soft tissue fixation, through the U.S. FDA 510(k) regulatory pathway. It โฆSee details»
4D Medicine raises £3.4m for unique biomaterial โฆ
Jul 25, 2024 4D Medicine Ltd is the parent company to two wholly owned subsidiaries, 4D Biomaterials Ltd and 4D Medical Devices Ltd. Respectively focusing on the development and commercialisation of new resorbable โฆSee details»
4D Medicine secured £3.4M for next-gen bioabsorbable implant โฆ
Jul 25, 2024 4D Medicine, a UK-based startup has raised £3.4 million in Series A investment.The round was led by Oshen Holdings and backed by DSW Ventures, SFC Capital โฆSee details»
4D Medicine Secures £3.4m to Advance Resorbable โฆ
Jul 25, 2024 Founded in 2020, 4D Medicine aims to enhance patient outcomes with its innovative biomaterials and medical devices. The companyโs facility can produce 1.5% of the global demand for medical-grade resorbable polymers. โฆSee details»
4D Medicine - Crunchbase Company Profile & Funding
When was the last funding round for 4D Medicine? 4D Medicine closed its last funding round on Apr 4, 2020 from a Seed round. Who are 4D Medicine 's competitors? Alternatives and โฆSee details»
4D Medicine Secures $4.4m for Novel Biomaterial โฆ
Aug 25, 2024 4D Medicine has secured £3.4m ($4.4m) in a series A funding round to complete pre-clinical trials of its unique biomaterial platform for use with surgical devices and a wide range of 3D-printed implants and seek FDA โฆSee details»
4D Medicine - VentureRadar
4D Medicine Limited specializes in the research, development, and commercialization of advanced resorbable biomaterials and implantable medical devices. Their core technology, โฆSee details»
4D Medicine โ VoxelMatters - The largest database of additive ...
The 4D Groupโs technology platform is centred around 4Degra, a patent protected resorbable photocurable resin based on unique polycarbonate urethane chemistry. A result of 15 years โฆSee details»
4Degra® | Bioabsorbable Polymers for Advanced Surgical Devices
4D is currently undertaking the regulatory groundwork to enable the use of 4Degra® in humans. ISO 10993: This international standard evaluates the biocompatibility of medical devices. It โฆSee details»
4DMT Announces RMAT Designation Granted by FDA for 4D-150
11 hours ago Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of โฆSee details»
4D Molecular Therapeutics receives RMAT designation for 4D-150 โฆ
9 hours ago 4D Molecular Therapeutics announced the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the โฆSee details»
4D Medicine raises £3.4m for unique biomaterial platform
Jul 25, 2024 4D Medicine โ a UK company whose innovative biomaterial has the potential to be used for a wide range of 3D printed implants and surgical devices โ has raised £3.4m ($4.4m) โฆSee details»
4D Medicine Raises £3.4M in Series A Funding - FinSMEs
Jul 25, 2024 4D Medicine, a Nottingham, UK-based company developing biomaterials for 3D printed implants and surgical devices, raised $3.4M in Series A funding.. The round was led by โฆSee details»
4DMT Announces RMAT Designation Granted by FDA for 4D-150 โฆ
11 hours ago About 4D-150 . 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with โฆSee details»
4D Medicine raises £3.4m in Series A funding - VoxelMatters
Aug 14, 2024 4D Medicine, previously known as 4D Biomaterials, a spin-out from the Universities of Birmingham and Warwick, has raised £3.4m ($4.4m) in a Series A investment. โฆSee details»